Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe

Background

Prisoners have a high prevalence of hepatitis C virus (HCV) infection but may find it difficult to access healthcare services. This may be related to risk behaviour including history of injecting drugs and marginalisation related to problem drug use/ opioid use disorder (OUD). Direct-acting antiviral products with superior efficacy and safety compared to interferon-based regimens offer HCV cure. Many citizens in Europe have been treated, although few received therapy in prisons.

Methods

Analysis of prisoner HCV treatment need and policy determinants of clinical practice was completed for 5 EU countries. Evidence was collected from national statistical sources and peer-reviewed publications to describe prison populations and HCV prevalence, to map national prison/ HCV health policy or guidance. A consensus of important principles for prisoner HCV care was developed.

Results

Data from published sources describing prisoner HCV prevalence is limited. Prisoner population requiring HCV treatment is not known; estimated numbers based on analysis of evidence: England and Wales, 9000, France, 8000, Spain, 6000, Italy, 6000, Germany, 6000. Treatment access: national law defines right to equivalent care in all countries implying access to HCV therapy in prison similar to community; useful prisoner HCV guidance facilitating treatment decisions present in: 4 of 5 national/ regional HCV policy documents, 4 of 5 national prison healthcare policies. Four of five had practical prison HCV clinical guidelines. Despite existence of policy, implementation of guidance, and so HCV treatment, is suboptimal in many locations.

Conclusions

Prison is an important location to detect, address and treat HCV infection in people who may be underserved for healthcare and find it difficult to navigate community treatment pathways. This is often related to problems with OUD and resulting social inequity. HCV management in prisons must be improved. Policy and clinical practice guidance must be set to promote treatment, and practical steps to make treatment easy should be followed including education to promote engagement, set-up of optimal screening and work up processes with modern tools to reduce time needed/ achieve efficiency; programs to make it easier to get specialists’ input include remote working and nurse-led services.

MIXED GERM CELL TERATOMATOUS TUMOUR OF TESTIS IN ADULTS: DIAGNOSTIC CHALLENGES FOR A HISTOPATHOLOGIST (case report)

Background. Testicular tumours account for approximately 1-2 % of the total cancer cases in the male population globally and show higher incidence in the younger male age group of up to 15 years. The majority (~98 %) of testicular tumours are observed to be of the germ-cell origin which can either be of seminomatous type or non-seminomatous type. The non-seminomatous germ cell neoplasm may be pure or of mixed subtype. Objective was to emphasize the rare case of mixed germ cell teratomatous tumour of testis in adult man.Methods.  A mixed germ cell teratomatous tumour of testis comprising of yolk sac tumour and embryonal carcinoma in an adult Indian male is reported in the research.Results. A 45 year-old Indian male presented with enlargement of right testis which was found to be an encapsulated right testicular tumour on exploratory surgery which was followed by radical orchiectomy. Serum AFP and β-hCG levels were elevated to 380 ng/ml and 590 mg/ml respectively. Histopathology revealed a mixed germ cell teratomatous tumour of testis comprising of yolk sac tumour and embryonal carcinoma.Conclusions. In adults teratomas occur usually as a component of mixed germ cell tumours. However in the present case teratomatous embryoid yolk sac germ cell tumour of testis was observed in an Indian adult male. The prognosis of embryoid germ cell tumours of testis is generally poor. The possibility of this condition should always be considered in all cases that present with a testicular lump.

Modelling invasive group A streptococcal disease using bioluminescence

BACKGROUND

The development of vaccines and evaluation of novel treatment strategies for invasive group A streptococcal (iGAS) disease requires suitable models of human infection that can be monitored longitudinally and are preferably non-invasive. Bio-photonic imaging provides an opportunity to reduce use of animals in infection modelling and refine the information that can be obtained, however the range of bioluminescent GAS strains available is limited. In this study we set out to develop bioluminescent iGAS strains for use in in vivo pneumonia and soft tissue disease models.

RESULTS

Using clinical emm1, emm3, and emm89 GAS strains that were transformed with constructs carrying the luxABCDE operon, growth and bioluminescence of transformed strains were characterised in vitro and in vivo. Emm3 and emm89 strains expressed detectable bioluminescence when transformed with a replicating plasmid and light production correlated with viable bacterial counts in vitro, however plasmid instability precluded use in the absence of antimicrobial pressure. Emm89 GAS transformed with an integrating construct demonstrated stable bioluminescence that was maintained in the absence of antibiotics. Bioluminescence of the emm89 strain correlated with viable bacterial counts both in vitro and immediately following infection in vivo. Although bioluminescence conferred a detectable fitness burden to the emm89 strain during soft tissue infection in vivo, it did not prevent dissemination to distant tissues.

CONCLUSION

Development of stably bioluminescent GAS for use in vitro and in vivo models of infection should facilitate development of novel therapeutics and vaccines while also increasing our understanding of infection progression and transmission routes.

Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs

INTRODUCTION

Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation leading to decreased systemic artery pressure and pulmonary artery pressure (PAP). This study compared the effects of fasudil administered as either an intravenous infusion or inhaled aerosol in newborn lambs.

HYPOTHESIS

Inhaled aerosol delivery of fasudil will provide selective pulmonary vasodilation when compared with intravenous administration.

METHODS

Newborn lambs (∼11 days) were surgically instrumented and mechanically ventilated under anesthesia. A pulmonary artery catheter and ultrasonic flow probe were inserted to measure hemodynamics. Acute PH was pharmaceutically induced via continuous intravenous infusion of thromboxane. After achieving a 2- to 3-fold elevation of PAP, fasudil was administered either as intravenous infusion (2.5 mg/kg) or inhaled aerosol (100 mg of fasudil in 2 mL of saline). Changes in PAP, mean systemic arterial pressure (MABP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), cardiac output, and heart rate were assessed. In addition, plasma concentrations of fasudil were measured.

RESULTS

Both routes of fasudil delivery produced significant decreases in PAP and PVR but also produced similar decreases in MABP and SVR. The C_max for intravenous fasudil was greater than that for inhaled fasudil.

CONCLUSIONS

These results suggest inhaled fasudil lacks pulmonary selectivity when compared with intravenous fasudil.

210Po concentration in selected diatoms and dinoflagellates in the northern Arabian Gulf

Marine phytoplankton is a primary producer in the ocean that forms the base of the marine food web and supports the pelagic food chain. The two dominant groups of phytoplankton observed in northern Gulf waters are diatoms and dinoflagellates. The diatoms outnumber dinoflagellates in the Gulf waters. This study presents baseline information on the concentration of ²¹⁰Po among selected phytoplankton in the northern Gulf. The concentration among diatoms varies between 6.99 and 11.4 Bq kg^-1 wwt, whereas a higher concentration range of 8.51-15.41 Bq kg^-1 wwt was observed among dinoflagellates. The diatoms analyzed includes Thalassiosira spp. - 10.2-11.4 Bq kg^-1 wwt; Chaetoceros spp. - 6.99-7.14 Bq kg^-1 wwt; Rhizosolenia spp. - 9.12-9.95 Bq kg^-1 wwt. The analyzed dinoflagellate genera include Gymnodinium spp. - 8.51-8.78 Bq kg^-1 wwt; Noctiluca spp. - 15.2-15.4 Bq kg^-1 wwt; and Karenia spp. - 14.1-14.9 Bq kg^-1 wwt. The ²¹⁰Po concentration in seawater shows a seasonal variation, with a higher concentration range of 0.70 and 0.58 mBq L^-1 during summer and autumn, whereas a lower range in concentration of 0.38 and 0.30 mBq L^-1 occurring during winter and spring. The resultant computed concentration factors vary between 2 ∗ 10⁴-5 ∗ 10⁴ demonstrating a significant ²¹⁰Po enrichment in the base of the pelagic food chain.

EMD-DWT based transform domain feature reduction approach for quantitative multi-class classification of breast lesions

Using a large set of ultrasound features does not necessarily ensure improved quantitative classification of breast tumors; rather, it often degrades the performance of a classifier. In this paper, we propose an effective feature reduction approach in the transform domain for improved multi-class classification of breast tumors. Feature transformation methods, such as empirical mode decomposition (EMD) and discrete wavelet transform (DWT), followed by a filter- or wrapper-based subset selection scheme are used to extract a set of non-redundant and more potential transform domain features through decorrelation of an optimally ordered sequence of N ultrasonic bi-modal (i.e., quantitative ultrasound and elastography) features. The proposed transform domain bi-modal reduced feature set with different conventional classifiers will classify 201 breast tumors into benign-malignant as well as BI-RADS⩽3, 4, and 5 categories. For the latter case, an inadmissible error probability is defined for the subset selection using a wrapper/filter. The classifiers use train truth from histopathology/cytology for binary (i.e., benign-malignant) separation of tumors and then bi-modal BI-RADS scores from the radiologists for separating malignant tumors into BI-RADS category 4 and 5. A comparative performance analysis of several widely used conventional classifiers is also presented to assess their efficacy for the proposed transform domain reduced feature set for classification of breast tumors. The results show that our transform domain bimodal reduced feature set achieves improvement of 5.35%, 3.45%, and 3.98%, respectively, in sensitivity, specificity, and accuracy as compared to that of the original domain optimal feature set for benign-malignant classification of breast tumors. In quantitative classification of breast tumors into BI-RADS categories⩽3, 4, and 5, the proposed transform domain reduced feature set attains improvement of 3.49%, 9.07%, and 3.06%, respectively, in likelihood of malignancy and 4.48% in inadmissible error probability compared to that of the original domain optimal subset. In summary, the construction of a transform domain reduced feature set by extracting complementary information from a large set of available bi-modal features and use of qualitative bi-modal BI-RADS can contribute to improved quantitative classification of breast tumors and thereby help reduce the number of unnecessary biopsies, securing a nearly minimum chance of a life-endangering diagnosis.

A 15-year single centre retrospective study of antiphospholipid syndrome patients from Northern Malaysia

BACKGROUND

Antiphospholipid syndrome (APS) is an autoimmune disorder characterised by thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPLs) based on the Sydney criteria. We aimed to explore the clinico-laboratory features and treatment strategies of APS patients retrospectively.

METHODOLOGY

The medical records of APS patients registered under Hospital Universiti Sains Malaysia (Kelantan state) between 2000 and 2015 were reviewed.

RESULTS

A total of 17 APS subjects (age 40.7 ± 12.8 years) including 11 primary (64.7%) and six secondary APS (35.3%) patients were identified. The follow-up period was 9.5 ± 6.7 years with male:female ratio of 1.0:4.7. Pregnancy morbidity was the most common clinical manifestation (11/14; 78.6%) followed by recurrent venous thrombosis (10/17; 58.8%). For other clinical features, menorrhagia was the most frequently observed manifestation (4/14; 28.6%) followed by aPLs-associated thrombocytopenia (4/17; 23.5%) and ovarian cyst (3/14; 21.4%). LA and aCL were positive in 94.1% (16/17) and 81.8% (9/11) of the patients, respectively. APTT value (76.7 ± 17.0 sec) was significantly high (p < 0.05). Low intensity warfarin alone was successful to maintain target INR (2.0 - 3.0) and prevent recurrence of thrombosis.

CONCLUSION

The tendency of pregnancy morbidity in this cohort of Malaysian Kelantanese APS patients was high compared to other previously reported APS cohorts. Low intensity warfarin was successful in preventing recurrence of thrombosis, however, APS women receiving long-term anticoagulants should be monitored for possible occurrence of menorrhagia and ovarian cysts.

Abstract NTOC-077: ORALLY ACTIVE LOW MOLECULAR WEIGHT HEPARIN TAUROCHOLATE AND DEOXYCHOLATE CONJUGATE FOR THE INHIBITION OF THE PROGRESSION OF METASTATIC OVARIAN CANCER

PURPOSE: Ovarian cancer is one of the major aggressive cancer which is not manageable blocking a single pathway. Recently, chemically modified low molecular weight heparin (LMWH) derivatives have shown good anti-cancer activity targeting various biochemical parameters, such as, transforming growth factor beta 1 (TGFβ-1), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), heparin-like growth factor (HGF), CXCL-12, and CXCL-9. In this study, we have focused on TGFβ-1 and VEGF that are known to promote metastatic ovarian cancer progression and use an orally LMWH-taurocholate conjugated with tetrameric deoxycholic acid, namely LHTD4, to successfully inhibit the progression at different stages of ovarian metastasis cancer.

EXPERIMENTAL PROCEDURES: We performed the binding affinity of TGFβ-1 and VEGF with LHTD4. We carried out in vitro phosphorylation assays of the consecutive receptors of TGFβ-1 and VEGF (TGF-β-1R1 and VEGFR2, respectively). Effects of LHTD4 on in vitro SKOV3-LUC cell migration (induced by TGFβ-1 and VEGF), spheroid formation, and the epithelial to mesenchymal transition (EMT) were investigated. We prepared a formulation of LHTD4 and a synthetic bile acid-based absorption enhancer, DCK (L-lysine- deoxycholylethylamine), to enable the oral absorption. The in vivo anti-metastatic effect of LHTD4 was evaluated in an intraperitoneal adhesion model and an orthotopic SKOV3-LUC ovarian cancer model. We measured the luciferase activity of the mice every week to check the progression of the cancer.

RESULTS: LHTD4 inhibited the migration of SKOV3-LUC cells 10-fold greater than the control group. LHTD4 also blocked the VEGF induced SKOV3-LUC spheroid formation. LHTD4 effectively inhibited ligand-induced VEGFR2 and TGFβ-1R1 phosphorylated. The expressions of EMT marker proteins such as Vimentin and Snail were prevented by LTHD4 treatment in in vitro studies with TGFβ-1 treated SKOV3-LUC cells. In orthotopic model ovarian metastasis model, the treatment with LHTD4 (5 mg/kg daily, orally) significantly inhibited the growth and organ metastasis progression compared to the control: LHTD4-treated mice showed 20-times lower luciferase activity than that of control mice. Finally, the intraperitoneal adhesion of the SKOV3-LUC cells was also decreased robustly in mice which received LHTD4 daily.

CONCLUSION: LHTD4 is one of the promising candidate for the inhibition of the progression of epithelial ovarian cancer. We report that the oral formulation of LHTD4/DCK complex could be a good choice for the treatment of metastatic ovarian cancer as it can target multiple pathways of metastasis. LHTD4 primarily showed anti-metastatic effects via blocking of TGFβ-1 and VEGF signaling pathway at different stages of metastasis progress.

Citation Format: Farzana Alam, Mohammad Rezwanul Haque, Taslim A. Al-Hilal, Fakhrul Ahsan, Youngro Byun. ORALLY ACTIVE LOW MOLECULAR WEIGHT HEPARIN TAUROCHOLATE AND DEOXYCHOLATE CONJUGATE FOR THE INHIBITION OF THE PROGRESSION OF METASTATIC OVARIAN CANCER [abstract]. In: Proceedings of the 11th Biennial Ovarian Cancer Research Symposium; Sep 12-13, 2016; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(11 Suppl):Abstract nr NTOC-077.

Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management

Metronomic chemotherapy has translated into favorable toxicity profile and capable of delaying tumor progression. Despite its promise, conventional injectable chemotherapeutics are not meaningful to use as metronomic due to the necessity of frequent administration for personalized therapy in long-term cancer treatments. This study aims to exploit the benefits of the oral application of carboplatin as metronomic therapy for non-small cell lung cancer (NSCLC). We developed an orally active carboplatin by physical complexation with a deoxycholic acid (DOCA). The X-ray diffraction (XRD) patterns showed the disappearance of crystalline peaks from carboplatin by forming the complex with DOCA. In vivo pharmacokinetic (PK) study confirmed the oral absorption of carboplatin/DOCA complex. The oral bioavailability of carboplatin/DOCA complex and native carboplatin were calculated as 24.33% and 1.16%, respectively, when a single 50mg/kg oral dose was administered. Further findings of oral bioavailability during a low-dose daily administration of the complex (10mg/kg) for 3weeks were showed 19.17% at day-0, 30.27% at day-7, 26.77% at day-14, and 22.48% at day-21, demonstrating its potential for metronomic chemotherapy. The dose dependent antitumor effects of oral carboplatin were evaluated in SCC7 and A549 tumor xenograft mice. It was found that the oral carboplatin complex exhibited potent anti-tumor activity at 10mg/kg (74.09% vs. control, P<0.01) and 20mg/kg dose (86.22% vs. control, P<0.01) in A549 tumor. The number of TUNEL positive cells in the tumor sections was also significantly increased during oral therapy (3.95% in control, whereas 21.37% and 32.39% in 10mg/kg and 20mg/kg dose, respectively; P<0.001). The enhanced anti-tumor efficacy of oral metronomic therapy was attributed with its antiangiogenic mechanism where new blood vessel formation was notably decreased. Finally, the safety of oral complex was confirmed by three weeks toxicity studies; there were no significant systemic or local abnormalities found in mice at 10mg/kg daily oral dose. Our study thus describes an effective and safe oral formulation of carboplatin as a metronomic chemotherapy.

Peptic Ulcer Disease in Bangladesh: A Multi-centre Study

The incidence of peptic ulcer has steadily declined through out the world. This decreasing trend is also noticeable in this subcontinent. The point prevalence of peptic ulcer (PUD) in Bangladesh was around 15% in eighties. The aim of this study was to see the present prevalence of peptic ulcer at endoscopy and to identify changing trends in the occurrence of peptic ulcer in Bangladesh. This retrospective analysis of the endoscopic records of multiple tertiary referral centres of Dhaka city were done from January 2012 to July 2013. A total of 5608 subjects were the study samples. We included those patients having peptic ulcer in the form of duodenal ulcer, benign gastric ulcer including pre-pyloric ulcer and gastric outlet obstruction due to peptic ulcer. Duodenal ulcer and benign gastric ulcer were found in 415(7.4%) and 184(3.28%) patients respectively and gastric outlet obstruction due to peptic ulcer was found in 23(0.40%) patients.

Remaking the American health care system: a positive reflection on the Affordable Care Act with emphasis on mental health care

Health care reform under the Patient Protection and Affordable Care Act (PPACA, ACA) of 2010 may be the most significant health care-related legislation enacted since the establishment of Medicare and Medicaid several decades ago. Over two years ago the U.S. Supreme Court upheld the constitutionality of the individual mandate of the Patient Protection and Affordable Care Act. This legislation has emerged as a significant and ambitious undertaking for all levels of the U.S. government. With the need to accommodate the estimated 30 million people projected over time to become newly insured it is increasingly important to understand the necessity of reform, how the legislation has been interpreted and implemented to fit the goals of the federal, state, and local governments, and what the potential benefits and consequences of changing the system are, in particular, as it relates to mental health care.

Pattern of Changes in the Findings among the Patients Undergoing Diagnostic Esophagogastroduodenoscopy in Bangladesh

This cross-sectional observational study was conducted in the Department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University, Sir Salimullah Medical College and Mitford Hospital, Holy family Red Crescent Medical College and Hospital and Popular Diagnostic Centre, Shantinagar branch, Dhaka, Bangladesh from January 2012 to July 2013. Study subjects were included in the study irrespective of age and sex having different upper GI tract. Complaints like dysphagia, heart burn, abdominal pain/dyspepsia, nausea, vomiting, haematemesis and/or malena, anorexia, unexplained anemia, weight loss etc. All the findings of oesophagus, stomach and duodenal lesions were observed and data were recorded. The results were considered positive based on the macroscopic appearance using standard diagnostic criteria. During the study period endoscopy was performed in 5608 subjects. Among which 2968(52.92%) were male and 2640(47.07%) were female. The patients age range from 7 years to 108 years. The majority of the patients were from 40-50 years. Normal findings were observed among 3321(59.21%) cases. Gastroduodenal erosions were present among 684(12.19%) cases, Oesophageal varices in 444(7.91%) cases, duodenal ulcer diseases in 415(7.40%) cases and gastric ulcer in 184(3.28%) cases. Ca stomach was found among 165(2.94%) cases. A number of diseases were identified through this procedure. Current study observed a large proportion of patients (40.79%) had positive upper GI endoscopy.

Characterization of Axillary Lymph Nodes as Normal, Reactive and Benign Using Conventional Ultrasonography

Background:Detection ofabnormalities ofaxillary lymph nodes is important for the diagnosis of different pathologies. Objective:The purpose of this present study was to see the accuracy of conventional USG for the differential diagnosis of axillary lymph nodes. Methodology: This cross sectional study was carried out in the Department of Radiology & Imaging at Bangabandhu Sheikh Mujib Medical University, Dhakafrom July 2012 to June 2013 for a period of one year. In this study normal healthy woman who came for screening of breast disease without any symptoms and did not have any abnormality on USG was included and werecategorized as normal patient. Axillary lymph nodes from the normal patients werecategorized as benign lymph nodes. Patients, who came with the complaints of mastalgia with normal breast findings, were included as patients with mastalgia. The lymph nodes from the patients of mastalgia were considered as reactive lymph nodes and patients with known breast cancer and lymph node metastasis were included as malignant patients. Metastatic lymph nodes from breast cancer patients was included diagnosed by cytopathology or histopathology as metastatic lymph nodes. Following patients’ second visit or final diagnosis the patients were included in the data set. Long axis diameter was taken as longest diameter in long axis. Result: In benign vs reactive lymph node the area under curve for long axis diameter was 0.534 (asymptotic significance 0.307), short axis diameter was 0.589 (asymptotic significance 0.007), sinus length 0.492 (asymptotic significance 0.798), cortical thickness was 0.684 (asymptotic significance 0.0001) short long ratio was 0.570 (asymptotic significance 0.033). In reactive vs metastatic the area under curve for long axis diameter was 0.464 (asymptotic significance 0.391), short axis diameter was 0.741 (asymptotic significance 0.000), sinus length 0.257 (asymptotic significance 0.037), cortical thickness was 0.625 (asymptotic significance 0.003) short long ratio was 0.791 (asymptotic significance 0.000), sinus long ratio 0.279 (asymptotic significance 0.040) cortex short axis ratio .516 (asymptotic significance 0.708).The cut off for short-long axis diameter ratio was 0.43, for short axis was 0.66cm and for cortical thickness 0.37cm. In benign vs metastasis lymph node the area under curve for long axis diameter was 0.533 (asymptotic significance 0.417), short axis diameter was 0.797 (asymptotic significance 0.000), sinus length 0.254 (asymptotic significance 0.000), cortical thickness was 0.757 (asymptotic significance 0.0001) short long ratio was 0.847 (asymptotic significance 0.0001), sinus long ratio 0.241 (asymptotic significance 0.0001) cortex short axis ratio .661 (asymptotic significance 0.0001). Conclusion: To differentiate benign, reactive and metastatic lymph node, cortical thickness and shape are the important parameters. Journal of Science Foundation 2015;13(2):36-45DOI: http://dx.doi.org/10.3329/jsf.v13i2.27933

Targeting prion-like protein doppel selectively suppresses tumor angiogenesis

Controlled and site-specific regulation of growth factor signaling remains a major challenge for current antiangiogenic therapies, as these antiangiogenic agents target normal vasculature as well tumor vasculature. In this article, we identified the prion-like protein doppel as a potential therapeutic target for tumor angiogenesis. We investigated the interactions between doppel and VEGFR2 and evaluated whether blocking the doppel/VEGFR2 axis suppresses the process of angiogenesis. We discovered that tumor endothelial cells (TECs), but not normal ECs, express doppel; tumors from patients and mouse xenografts expressed doppel in their vasculatures. Induced doppel overexpression in ECs enhanced vascularization, whereas doppel constitutively colocalized and complexed with VEGFR2 in TECs. Doppel inhibition depleted VEGFR2 from the cell membrane, subsequently inducing the internalization and degradation of VEGFR2 and thereby attenuating VEGFR2 signaling. We also synthesized an orally active glycosaminoglycan (LHbisD4) that specifically binds with doppel. We determined that LHbisD4 concentrates over the tumor site and that genetic loss of doppel in TECs decreases LHbisD4 binding and targeting both in vitro and in vivo. Moreover, LHbisD4 eliminated VEGFR2 from the cell membrane, prevented VEGF binding in TECs, and suppressed tumor growth. Together, our results demonstrate that blocking doppel can control VEGF signaling in TECs and selectively inhibit tumor angiogenesis.

Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models

CONTEXT

As a class of angiogenesis inhibitors, heparin conjugates have shown significant effectiveness in several studies.

OBJECTIVES

The purpose of our current study is to evaluate the effectiveness and safety of infusing the conjugate of low molecular weight heparin and taurocholate (LHT7), which has been developed as a potent angiogenesis inhibitor.

METHODS

To evaluate its safety, the method of intravenous infusion was compared with its i.v. bolus administration. Intravenous infusion was administered at a rate of 400 μl/min/kg of body weight for 30 min. Pharmacokinetic (PK) analysis, organ accumulation, and plasma concentration profiles of LHT7 were measured. The anticancer effect of LHT7 was evaluated in murine and human xenograft models, and preclinical studies were performed in SD rats and beagle dogs.

RESULTS

The results of the PK studies showed reduced organ accumulation in mice and the AUC(0-96 h) (area under the curve) was increased up to 1485 ± 125 h × μg/ml. The efficacy, at dose 1 mg/kg/2 d was higher for i.v. infusion than for i.v. bolus administration in both murine and human cancer models. The preclinical studies showed the safety dose of LHT7 is less than 20 mg/kg in SD rats and in the next safety analysis in beagle dogs showed that there were no organ-specific adverse effects in higher doses, such as, 12 mg/kg. LHT7 showed sustained effects with minimized adverse events when administered through i.v. infusion.

CONCLUSIONS

LHT7 (i.v. infusion) could be safely used for further clinical development as a multi-targeting anti-angiogenic agent.